Related Experiment Video
Updated: Apr 7, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
Krishnansu S Tewari1, Ramez N Eskander1, Bradley J Monk2
1The Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, California.
Abstract:
The FDA approval of the PARP inhibitor olaparib for fourth-line therapy of germline BRCA1/2-mutated ovarian cancer represents the first registered indication for this class of drugs in any disease. PARP is a family of proteins involved in the repair of single-strand DNA breaks. High-grade serous ovarian carcinomas with BRCA deficiencies may be particularly vulnerable to both direct and indirect effects of PARP inhibition. This phenotype frequently arises as a consequence of defects in the repair of damaged DNA, rendering cancer cells susceptible to DNA-damaging platinum compounds and targeted therapies affecting homologous recombination repair (HRR). When cells already deficient in HRR are exposed to PARP inhibitors, apoptosis occurs by way of synthetic lethality. In this review, we trace the clinical development of olaparib for women with recurrent epithelial ovarian carcinoma harboring germline BRCA mutations, a biomarker for HRR deficiency present in 15% to 20% of cases. Clinical trials highlighted include not only those pivotal studies that have led to regulatory approval in the United States and in Europe, but also those in which olaparib was studied in novel combinations, including chemotherapy and antiangiogenesis agents.
Insights
Olaparib, a PARP inhibitor, is the first drug approved for BRCA-mutated ovarian cancer. This targeted therapy exploits DNA repair defects for synthetic lethality, offering a new treatment option for patients with specific genetic profiles.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors represent a novel class of targeted cancer therapies.
- Germline BRCA1/2 mutations are key biomarkers for homologous recombination repair (HRR) deficiency in ovarian cancer.
- Synthetic lethality is a therapeutic strategy exploiting cancer-specific vulnerabilities.
Purpose of the Study:
- To review the clinical development and FDA approval of olaparib for ovarian cancer.
- To explore the mechanism of action of PARP inhibitors in BRCA-deficient tumors.
- To highlight clinical trials involving olaparib in various treatment settings and combinations.
Main Methods:
- Review of pivotal clinical trials and regulatory submissions for olaparib.
- Analysis of preclinical data on PARP inhibition and synthetic lethality.
- Examination of studies investigating olaparib in combination therapies.
Main Results:
- Olaparib received FDA approval for fourth-line treatment of germline BRCA1/2-mutated ovarian cancer.
- BRCA deficiency creates synthetic lethality when cells are exposed to PARP inhibitors, leading to apoptosis.
- Clinical trials demonstrated olaparib's efficacy in recurrent epithelial ovarian carcinoma with HRR deficiency.
Conclusions:
- Olaparib is the first approved PARP inhibitor, marking a significant advancement in ovarian cancer treatment.
- Targeting DNA repair pathways, like HRR, offers a promising strategy for precision oncology.
- Further research is ongoing to explore olaparib in novel combinations for improved patient outcomes.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:02Long-patch Base Excision Repair